European Companies Search Engine
EU funding (€2,532,975): Immune DIREcted and Cancer-selective immunoTherapy Hor13 Nov 2018 EU Research and Innovation programme "Horizon"
Overview
Text
Immune DIREcted and Cancer-selective immunoTherapy
I-DireCT is a European Industrial Doctorate (EID) training network designed to provide training and carry out breakthrough research on the rapidly expanding and high impact field of cancer immunotherapy in a carefully integrated academic and inter-sectoral programme. Hereby, we aim to develop next-generation immunotherapeutics and deliver a set of early stage researchers uniquely qualified for a career in academia and/or industry. Current immunomodulatory antibodies that target pivotal immune checkpoints have revolutionized the field of oncology. However, off-tumor activity limits their application. The objective of I-Direct is to address this issue by 1. developing innovative bispecific antibodies and immunocytokines with tumor-restricted immunostimulatory effects and 2. developing optimized delivery systems to ensure optimal timed release of bio-active drug. Hereto, I-DireCT combines state-of-the-art industrial design of nanotech-based drug formulations with innovative academic and industrial immunotherapeutic concepts into the next-generation of cancer immunotherapeutics. At the core of I-DireCT is its training objective to offer a cutting-edge multidisciplinary training programme that will enable outstanding young scientists to generate breakthrough ideas and assume leading positions in academia and industry. This training programme includes an array of disciplines, ranging from biomedical sciences (e.g. immunology, antibody engineering) and physical sciences (e.g. chemistry, material science) to drug design & development. Industrial partners are central to the programme and provide pivotal inter-sectoral expertise on how to translate scientific discoveries into commercial reality, with each ESR being appointed at an inter-sectoral partner for 18 months, as well as through additional secondments. Further, I-Direct will enable long-term multi-disciplinary research and fosters bilateral co-operations between academia and industry.
Funded Companies:
| Company name | Funding amount |
| ACADEMISCH ZIEKENHUIS GRONINGEN | €922,291 |
| Inocure s.r.o. | €469,743 |
| KAHR MEDICAL Ltd. | €256,181 |
| Surflay Nanotec GmbH | €505,577 |
| UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT | €379,183 |
Source: https://cordis.europa.eu/project/id/813871
The filing refers to a past date, and does not necessarily reflect the current state.
The visualizations for "ACADEMISCH ZIEKENHUIS GRONINGEN - EU funding (€2,532,975): Immune DIREcted and Cancer-selective immunoTherapy"
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
